The global leader in
design and manufacture of
Bacterial Extracellular Vesicles
The more effective delivery of Bacterial Extracellular Vesicles, or BEVs, at lower cost is critical for the advancement of human health.
The global leader in
design and manufacture of
Bacterial Extracellular Vesicles
The more effective delivery of Bacterial Extracellular Vesicles, or BEVs, at lower cost is critical for the advancement of human health.
The global leader in
design and manufacture of
Bacterial Extracellular Vesicles
The more effective delivery of Bacterial Extracellular Vesicles, or BEVs, at lower cost is critical for the advancement of human health.
Our Mission
Our Mission
From Microbiome to Medicine
From Microbiome to Medicine
Expora is creating an entirely new product category to improve human health and disease
For decades, probiotics have promised health benefits, but their results have been frustratingly inconsistent. Now, Expora is cracking the code on what makes probiotics actually work, with potentially transformative implications.
Probiotic bacteria deliver health benefits via compounds they secrete and deliver to human tissues, in particular, tiny particles called bacterial extracellular vesicles (BEVs). These nanosized 'bubble' deliver multiple bioactive compounds directly to human tissues, but until now, there's been no way to reliably manufacture BEVs at scale.
Expora has developed breakthrough patent-pending technology that enables, for the first time, the scalable manufacturing of purified BEVs. Instead of relying on unpredictable live bacteria that may or may not survive storage and oral administration and deliver benefits, Expora's approach allows precise, consistent dosing of the active BEVs that actually drive health outcomes.
The result? An entirely new category of products spanning consumer wellness, scientific research, and therapeutic applications—all built on a platform that could redefine how we approach human health and disease prevention.
Born from cutting-edge research at the University of Maryland, College Park, Expora represents the next evolution of probiotics to deliver on the promise of precise, predictable, and potent health benefits.
Expora is creating an entirely new product category to improve human health and disease
For decades, probiotics have promised health benefits, but their results have been frustratingly inconsistent. Now, Expora is cracking the code on what makes probiotics actually work, with potentially transformative implications.
Probiotic bacteria deliver health benefits via compounds they secrete and deliver to human tissues, in particular, tiny particles called bacterial extracellular vesicles (BEVs). These nanosized 'bubble' deliver multiple bioactive compounds directly to human tissues, but until now, there's been no way to reliably manufacture BEVs at scale.
Expora has developed breakthrough patent-pending technology that enables, for the first time, the scalable manufacturing of purified BEVs. Instead of relying on unpredictable live bacteria that may or may not survive storage and oral administration and deliver benefits, Expora's approach allows precise, consistent dosing of the active BEVs that actually drive health outcomes.
The result? An entirely new category of products spanning consumer wellness, scientific research, and therapeutic applications—all built on a platform that could redefine how we approach human health and disease prevention.
Born from cutting-edge research at the University of Maryland, College Park, Expora represents the next evolution of probiotics to deliver on the promise of precise, predictable, and potent health benefits.
Bacterial Extracellular Vesicles (BEVs)
Nature's Delivery Vehicles
Bacterial Extracellular Vesicles (BEVs)
Nature's Delivery Vehicles
Bacterial Extracellular Vesicles (BEVs)
Nature's Delivery Vehicles
Our Vision
Our Vision
The gut microbiome controls immunity, brain function, and metabolism, driving an ~$8B probiotics market and emergin pharma applications.
Beneficial bacteria ("probiotics") generate BEVs—nanoscale vesicles that survive the GI tract and deliver potent bioactive cargo directly to gut tissues. But probiotics often underdeliver because they rely on live bacteria surviving manufacturing and storage and producing enough BEVs in vivo, with added safety risks in vulnerable patients.
The field needs a predictable, precise BEV dose at reasonable cost and quality. Until now, BEVs have been too costly and inconsistent to manufacture at scale—Expora’s patent-pending platform changes that by establishing the an industrial GMP process for BEV manufacturing and design.
Expora's BEV-enabled advantage:
Expora's BEV-enabled advantage:
Produced by FDA-designated Generally Regarded As Safe (GRAS) probiotics studied in hundreds of clinical trials.
Produced by FDA-designated Generally Regarded As Safe (GRAS) probiotics studied in hundreds of clinical trials.
Oral delivery. Tiny capsule. No injections.
Oral delivery. Tiny capsule. No injections.
Pharma-level quality. Consumer-level affordability.
Pharma-level quality. Consumer-level affordability.
Gut-targeted, multi-specific targeting to meet ideal target product profiles in complex diseases.
Gut-targeted, multi-specific targeting to meet ideal target product profiles in complex diseases.
Our Vision
The gut microbiome controls immunity, brain function, and metabolism, driving an ~$8B probiotics market and emergin pharma applications.
Beneficial bacteria ("probiotics") generate BEVs—nanoscale vesicles that survive the GI tract and deliver potent bioactive cargo directly to gut tissues. But probiotics often underdeliver because they rely on live bacteria surviving manufacturing and storage and producing enough BEVs in vivo, with added safety risks in vulnerable patients.
The field needs a predictable, precise BEV dose at reasonable cost and quality. Until now, BEVs have been too costly and inconsistent to manufacture at scale—Expora’s patent-pending platform changes that by establishing the an industrial GMP process for BEV manufacturing and design.
Expora's BEV-enabled advantage:
Produced by FDA-designated Generally Regarded As Safe (GRAS) probiotics studied in hundreds of clinical trials.
Oral delivery. Tiny capsule. No injections.
Pharma-level quality. Consumer-level affordability.
Gut-targeted, multi-specific targeting to meet ideal target product profiles in complex diseases.
Our Vision
Our Vision
The Expora Platform™ overcomes critical EV manufacturing barriers to deliver a transformative new biotechnology modality.
Expora is assembling a talented team to build and scale BEV manufacturing and grow the company at our Maryland-based facility.
We’re actively engaging partners and early investors to advance our BEV platform and products for pharma and consumer health applications. Get in touch to review data and plan next steps.